Replies to post #202528 on Biotech Values

[biomaven0]

It's also possible that once you have triggered cytokine release syndrome (or some variant) it might be too late to turn anything off because it becomes self-sustaining. Might be analogous to blowing out the lighted match that set a forest fire.

Not to say a rheostat might not be useful - it would at least allow you to slowly increase the dosage over time. An interesting analogy from a targeted therapy might be Ariad's brigatinib - there starting with a 180mg dose sometimes triggered early onset severe pulmonary symptoms, which might well be immune related (tumor release syndrome). But a week at a lower 90mg dose before stepping up to 180mg seems to avoid this issue.

Peter